1025 related articles for article (PubMed ID: 15470215)
1. Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Liaw YF; Sung JJ; Chow WC; Farrell G; Lee CZ; Yuen H; Tanwandee T; Tao QM; Shue K; Keene ON; Dixon JS; Gray DF; Sabbat J;
N Engl J Med; 2004 Oct; 351(15):1521-31. PubMed ID: 15470215
[TBL] [Abstract][Full Text] [Related]
2. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine as initial treatment for chronic hepatitis B in the United States.
Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
[TBL] [Abstract][Full Text] [Related]
4. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
5. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
6. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
7. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
8. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
9. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
10. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
11. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
13. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
14. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
19. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Eun JR; Lee HJ; Kim TN; Lee KS
J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
